Phaseline

Companies › Jiangsu BioJeTay Biotechnology

Jiangsu BioJeTay Biotechnology: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Hematology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
STSP-0601 for Injection
unclear - hemophilia treatment, likely coagulation factor or bypass agent
–Phase 3HemophiliaMar 2027
STSA-1301 subcutaneous injection–Phase 1Primary Immune Thrombocytopenia (ITP)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06929299STSA-1301 subcutaneous injectionPhase 1Primary Immune Thrombocytopenia (ITP)HematologySep 2026
NCT06922045STSP-0601 for InjectionPhase 3HemophiliaHematologyMar 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical Gritgen Therapeutics Shanghai RAAS Blood Products Forma Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.